Racial Disparities in Opioid Addiction Treatment Persist
A recent study published in JAMA Network Open has shed light on the significant disparities in access to medications for opioid addiction treatment among Black and Hispanic individuals compared to their white counterparts. The study, led by Utsha Khatri, an assistant professor at the Icahn School of Medicine at Mount Sinai, analyzed data from over 176,000 health events related to substance use, revealing that Black and Hispanic patients were 17.1% and 16.2% less likely, respectively, to receive medications like buprenorphine or naltrexone within 180 days of a substance use-related health care event.
The research, which drew data from multiple payers including Medicaid programs, Medicare Advantage, and private commercial insurers, highlighted the stark disparities in the quality of addiction treatment based on race. Notably, patients with government-backed insurance options, such as Medicaid or Medicare Advantage, were more likely to receive opioid addiction medications than those with commercial insurance.
While the study focused on buprenorphine and naltrexone, it did not include data on methadone, the most effective treatment for opioid use disorder. Buprenorphine and naltrexone are often considered lower-barrier options due to their less stringent requirements compared to methadone. Buprenorphine can be easily prescribed by most doctors and picked up at pharmacies, while naltrexone, marketed as Vivitrol, helps curb opioid cravings in individuals who are already abstinent.
Despite advancements in access to opioid addiction medications in recent years, racial disparities persist, reflecting broader systemic issues. Tracie Gardner, a policy advocate and founder of the National Black Harm Reduction Network, highlighted the limited access to health services in communities of color, stigma around medication-assisted treatment for addiction, and the disproportionate incarceration of Black individuals as contributing factors to the disparities.
To address these disparities, the study’s authors advocate for culturally sensitive care, standardized screening for opioid use disorder, and the integration of addiction care and medication prescribing across the health system. They point to Medicaid programs as a model for providing comprehensive coverage for all approved medications for opioid use disorder and offering coordinated care models.
In light of ongoing discussions to potentially roll back Medicaid benefits, the authors stress the importance of expanding Medicaid to eligible individuals to ensure equitable access to addiction treatment. Despite recent decreases in overdose death rates, Khatri warns that not all communities have benefited equally from policy changes and funding allocations. It is crucial to prioritize marginalized communities that have historically been criminalized for substance use disorder to ensure that progress in addressing the opioid epidemic is inclusive and equitable.
